GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
120.19
+1.93 (1.63%)
At close: Oct 6, 2025, 4:00 PM EDT
120.15
-0.04 (-0.03%)
After-hours: Oct 6, 2025, 7:21 PM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $102.69M in the quarter ending June 30, 2025, with 45.63% growth. This brings the company's revenue in the last twelve months to $362.32M, up 48.70% year-over-year. In the year 2024, GeneDx Holdings had annual revenue of $305.45M with 50.79% growth.
Revenue (ttm)
$362.32M
Revenue Growth
+48.70%
P/S Ratio
9.26
Revenue / Employee
$362,321
Employees
1,000
Market Cap
3.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
WGS News
- 5 days ago - GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award - Business Wire
- 6 days ago - GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth - Business Wire
- 11 days ago - GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference - Business Wire
- 18 days ago - GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors - Business Wire
- 4 weeks ago - GeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Seer Appoints Isaac Ro to its Board of Directors - GlobeNewsWire
- 2 months ago - Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS) - GlobeNewsWire
- 2 months ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire